Vaccine Manufacture and Supply – News and Features

A new vaccine to protect against deadly cholera has been made by grinding up genetically modified grains of rice. The first human trial has shown no obvious side effects and a good immune response.

The biotechnology company CureVac has announced that its Phase IIb/III clinical trial of the COVID-19 vaccine candidate CVnCoV demonstrates an interim efficacy of 47%.

The biotechnology company Novavax has announced that its Phase III clinical trial of the COVID-19 vaccine NVX-CoV2373 demonstrated an overall efficacy of 90.4%.

In this article, Keir Lewis explores how antibody testing can help provide invaluable data that can be used to inform the next stage of the vaccination program rollout.

The UK Medicines and Healthcare Regulatory Agency (MHRA) has authorized an extension to the UK approval of the Pfizer/BioNTech COVID-19 vaccine (BNT162b2), permitting its use in children aged 12–15.

The COVID-19 jab should be made free for everyone in India to boost uptake and curb the death toll from the infection, urge experts in a personal view (commentary) published in the online journal BMJ Global Health.

In this article, Amber Schmidtke explores why mRNA vaccines might chart our path to a safer, healthier future.

Scientists are concerned about the emergence of SARS-CoV-2 variants and whether existing vaccines will remain effective against them. Hence, the development of robust therapeutic systems, such as repurposing drugs, could aid in managing the pandemic more efficiently. This article discusses the different vaccines and potential treatments developed thus far.

COVID-19 vaccines are here, they are headed out globally and the world is faced with a giant logistical task: keeping these vaccines in their desired storage conditions to ensure stability and efficacy of every dose that goes into an arm. What are the storage requirements of vaccines and why does it matter?

As the pandemic enters its second year, the case for optimism has grown shakier. SARS-CoV-2 has been mutating. New variants have arisen in the United Kingdom, Brazil and South Africa, and seem intent on evading our remarkable new vaccines before we’ve even fully rolled them out.